特发性肺纤维化上皮生物标志物特征:PROFILE多中心队列分析
本研究基于PROFILE前瞻性纵向队列,采用两阶段发现与验证设计,在106例初治IPF患者及50名健康对照中通过123种标志物多重免疫分析发现4种可复制血清标志物,并在206例IPF患者中验证。结果显示基线SP-D和CA19-9在进展患者中显著升高,CA-125三个月内升高与死亡风险增加相关。
要点
- 基线SP-D和CA19-9在进展期IPF患者中显著高于稳定期患者。
- 血清上皮来源蛋白可用于预测IPF疾病进展和死亡。
核心结论
- 血清中化生上皮分泌的蛋白可预测IPF疾病进展和死亡。
研究设计与样本
- PROFILE为大型前瞻性纵向初治IPF队列,采用两阶段发现与验证设计。
- 发现阶段纳入106例IPF患者和50名年龄性别匹配健康对照,进行123种标志物多重免疫分析。
- 验证阶段纳入206例IPF患者,用独立免疫分析复制发现阶段标志物。
主要发现
- 发现阶段鉴定出SP-D、MMP7、CA19-9和CA-125四种可复制血清标志物。
- 组织学评估提示CA19-9和CA-125为上皮损伤标志物。
临床怎么用
- 可考虑检测基线SP-D和CA19-9辅助识别IPF进展高风险患者。
- 动态监测CA-125三个月变化有助于评估IPF死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal disorder with a variable disease trajectory. The aim of this study was to assess potential biomarkers to predict outcomes for people with IPF. METHODS: PROFILE is a large prospective longitudinal cohort of treatment-naive patients with IPF. We adopted a two-stage discovery and validation design using patients from the PROFILE cohort. For the discovery analysis, we examined 106 patients and 50 age and sex matched healthy controls from Nottingham University Hospitals NHS Trust and the Royal Brompton Hospital. We did an unbiased, multiplex immunoassay assessment of 123 biomarkers. We further investigated promising novel markers by immunohistochemical assessment of IPF lung tissue. In the validation analysis, we examined samples from 206 people with IPF from among the remaining 212 patients recruited to PROFILE Central England. We used the samples to attempt to replicate the biomarkers identified from the discovery analysis by use of independent immunoassays for each biomarker. We investigated the predictive power of the selected biomarkers to identify individuals with IPF who were at risk of progression or death. The PROFILE studies are registered on ClinicalTrials.gov, numbers NCT01134822 (PROFILE Central England) and NCT01110694 (PROFILE Royal Brompton Hospital). FINDINGS: In the discovery analysis, we identified four serum biomarkers (surfactant protein D, matrix metalloproteinase 7, CA19-9, and CA-125) that were suitable for replication. Histological assessment of CA19-9 and CA-125 suggested that these proteins were markers of epithelial damage. Replication analysis showed that baseline values of surfactant protein D (46·6 ng/mL vs 34·6 ng/mL, p=0·0018) and CA19-9 (53·7 U/mL vs 22·2 U/mL; p<0·0001) were significantly higher in patients with progressive disease than in patients with stable disease, and rising concentrations of CA-125 over 3 months were associated with increased risk of mortality (HR 2·542, 95% CI 1·493-4·328, p=0·00059). INTERPRETATION: We have identified serum proteins secreted from metaplastic epithelium that can be used to predict disease progression and death in IPF. FUNDING: GlaxoSmithKline R&D and the UK Medical Research Council.
引用
- Maher TM, Oballa E, Simpson JK, et al. An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respir Med. 2017. PMID: 29150411. doi:10.1016/S2213-2600(17)30430-7
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。